Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Pegasys

- PMLiVE

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

- PMLiVE

Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types

Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes

- PMLiVE

Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS

Approximately 2.9 million people worldwide are affected by the neurological disease

- PMLiVE

Roche’s monoclonal antibody PiaSky approved by EC to treat rare blood disorder PNH

The drug is now the first monthly subcutaneous treatment authorised for use in this patient population

- PMLiVE

Roche’s Genentech and Sangamo enter neurodegenerative disease partnership worth over $1.9bn

According to WHO, neurological conditions are now the leading cause of ill health and disability worldwide

- PMLiVE

Roche’s subcutaneous Ocrevus granted MHRA approval to treat relapsing and primary MS

The NHS said it expects stock of the ten-minute injection to be available in the coming weeks

- PMLiVE

Roche announces CHMP recommendation for PiaSky in rare blood condition PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 20,000 people worldwide

- PMLiVE

Roche’s subcutaneous Ocrevus granted EC approval to treat relapsing and primary MS

The injection has the same twice-yearly schedule as the previously approved intravenous infusion

- PMLiVE

Roche and Ascidian enter neurological disease partnership worth over $1.8bn

More than three billion people worldwide were living with a neurological condition in 2021

- PMLiVE

Roche announces positive phase 3 results for Columvi combination in DLBCL

The most common form of non-Hodgkin lymphoma affects 160,000 people worldwide every year

- PMLiVE

Celltrion’s RoActemra biosimilar shows promise in phase 3 rheumatoid arthritis study

The chronic inflammatory disease affects approximately 1% of the population worldwide

- PMLiVE

Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children

The progressive neuromuscular disease affects approximately one in every 10,000 babies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links